Patents Assigned to AstraZeneca
  • NEW METHOD
    Publication number: 20130029956
    Abstract: The invention provides a novel method of treating respiratory diseases, e.g., pediatric asthma, in a continuing regimen with not more than one daily dose of the drug budesonide using a nebulizer.
    Type: Application
    Filed: October 4, 2012
    Publication date: January 31, 2013
    Applicant: ASTRAZENECA AB
    Inventor: ASTRAZENECA AB
  • QUINUCLIDINE DERIVATIVES AS MUSCARINIC M3 RECEPTOR ANTAGONISTS
    Publication number: 20130030001
    Abstract: The invention provides named compounds of formula (I), pharmaceutical compositions containing them, a process for preparing the pharmaceutical compositions and their use in therapy.
    Type: Application
    Filed: August 1, 2012
    Publication date: January 31, 2013
    Applicants: PULMAGEN THERAPEUTICS (SYNERGY) LIMITED, ASTRAZENECA AB
    Inventors: Richard James BULL, Elizabeth Anne SKIDMORE, Rhonan Lee FORD, Andrew Nigel MATHER, Antonio METE
  • Compounds and their use as IKACh blockers
    Patent number: 8361998
    Abstract: The invention relates to compounds according to Formula I: or a pharmaceutically acceptable salt thereof, wherein m, n, R1, R2, R3, R4, R5, x and y are as defined herein. Compounds according to Formula I are pharmacologically effective as potassium channel inhibitors, in particular inhibitors of the acetylcholine operated inward rectifying potassium channel current (i.e. IKACh blockers), and are believed to be useful in the treatment of cardiac arrhythmias, in particular supraventricular tacharrhythmias, such as atrial fibrillation and atrial flutter.
    Type: Grant
    Filed: November 29, 2011
    Date of Patent: January 29, 2013
    Assignee: AstraZeneca AB
    Inventors: Jonas Bostrõm, Hans Emtenäs, Kenneth Granberg, Mickael Mogemark, Antonio Llinas
  • NOVEL PIPERIDINE DERIVATIVES
    Publication number: 20130023562
    Abstract: The present invention provides a compound of a formula (I): wherein the variables are defined herein; to a process for preparing such a compound; and to the use of such a compound in the treatment of a chemokine (such as CCR3) mediated disease state.
    Type: Application
    Filed: July 27, 2012
    Publication date: January 24, 2013
    Applicant: ASTRAZENECA AB
    Inventors: Talbir Austin, David O'Sullivan, Matthew Perry, Brian Springthorpe
  • Biphenyloxyacetic acid derivatives for the treatment of respiratory disease
    Patent number: 8349897
    Abstract: The invention relates to substituted phenoxyacetic acids as useful pharmaceutical compounds for treating respiratory disorders, pharmaceutical compositions containing them, and processes for their preparation.
    Type: Grant
    Filed: December 20, 2010
    Date of Patent: January 8, 2013
    Assignee: Astrazeneca AB
    Inventors: Timothy Jon Luker, Rukhsana Tanseem Mohammed, Mark Dickinson, Stephen Thom
  • QUINAZOLINE DERIVATIVES
    Publication number: 20130005727
    Abstract: The invention concerns quinazoline derivatives of Formula I wherein each of Q1, Z, R1 and Q2 have any of the meanings defined in the description; processes for their preparation, pharmaceutical compositions containing them and their use in the manufacture of a medicament for use as an antiproliferative agent in the prevention or treatment of tumours which are sensitive to inhibition of erbB receptor tyrosine kinases.
    Type: Application
    Filed: September 10, 2012
    Publication date: January 3, 2013
    Applicant: ASTRAZENECA AB
    Inventors: Robert Hugh BRADBURY, Laurent Francois Andre HENNEQUIN, Jason Grant KETTLE
  • QUINICLIDINE DERIVATIVES OF (HETERO) ARYLCYCLOHEPTANECARBOXYLIC ACID AS MUSCARINIC RECEPTOR ANTAGONISTS
    Publication number: 20130005695
    Abstract: The invention provides compounds of formula (I) wherein R4 is a group of formula (II) or (IIIa) or (IIIb) and R1, R2, R3, R5, a, b and X are as defined in the specification, a process for their preparation, pharmaceutical compositions containing them, a process for preparing pharmaceutical compositions, their use in therapy and intermediates of use in their preparation
    Type: Application
    Filed: May 15, 2012
    Publication date: January 3, 2013
    Applicant: AstraZeneca AB
    Inventors: Rhonan Ford, Andrew Mather, Antonio Mete
  • CHEMICAL COMPOUNDS
    Publication number: 20130005725
    Abstract: There is provided pyrimidinyl compounds of Formula (I), wherein: R2 is or pharmaceutically acceptable salts thereof, processes for their preparation, pharmaceutical compositions containing them and their use in therapy.
    Type: Application
    Filed: July 2, 2012
    Publication date: January 3, 2013
    Applicant: AstraZeneca AB
    Inventors: Kevin Michael Foote, Johannes Wilhelmus Maria Nissink, Paul Turner
  • Pyrazole derivatives as 11-beta-HSD1 inhibitors
    Patent number: 8344016
    Abstract: A compound of formula (I): and pharmaceutically-acceptable salts thereof wherein the variable groups are defined within; their use in the inhibition of 11?HSD1, processes for making them and pharmaceutical compositions comprising them are also described.
    Type: Grant
    Filed: September 9, 2010
    Date of Patent: January 1, 2013
    Assignee: AstraZeneca AB
    Inventors: Martin John Packer, James Stewart Scott, Andrew Stocker, Paul Robert Owen Whittamore
  • Azaquinolinone derivatives and uses thereof
    Patent number: 8343996
    Abstract: The present invention provides compounds and methods for treating or preventing the development of a disease, disorder, or condition in a subject or patient.
    Type: Grant
    Filed: November 13, 2009
    Date of Patent: January 1, 2013
    Assignee: AstraZeneca AB
    Inventor: Mark E. Duggan
  • Compounds
    Patent number: 8338587
    Abstract: The present invention provides named compounds of formula (I) and pharmaceutical compositions containing them and their use in therapy.
    Type: Grant
    Filed: March 30, 2010
    Date of Patent: December 25, 2012
    Assignee: AstraZeneca AB
    Inventors: Frank Burkamp, Peter Hansen, Balint Gabos, Håkan Bladh
  • Pharmaceutical Composition
    Publication number: 20120321712
    Abstract: The invention relates to pharmaceutical compositions containing rosuvastatin calcium of formula (I) and processes for their manufacture.
    Type: Application
    Filed: May 18, 2012
    Publication date: December 20, 2012
    Applicant: ASTRAZENECA UK LIMITED
    Inventors: Joseph Richard Creekmore, Sanjeev Hukmichand Kothari, Bradford J. Mueller, Yingxu Peng
  • Formulation
    Patent number: 8329680
    Abstract: The invention relates to a novel sustained release pharmaceutical formulation adapted for administration by injection containing the compound 7?-[9-(4,4,5,5,5-pentafluoropentylsulphinyl)nonyl]oestra-1,3,5(10)-triene-3,17?-diol, more particularly to a formulation adapted for administration by injection containing the compound 7?-[9-(4,4,5,5,5-pentafluoropentylsulphinyl)nonyl]oestra-1,3,5(10)-triene-3,17?-diol in solution in a ricinoleate vehicle which additionally comprises at least one alcohol and a non-aqueous ester solvent which is miscible in the ricinoleate vehicle.
    Type: Grant
    Filed: October 15, 2008
    Date of Patent: December 11, 2012
    Assignee: AstraZeneca AB
    Inventors: John R Evans, Rosalind U Grundy
  • GLP-1 receptor agonist bioassays
    Patent number: 8329419
    Abstract: Provided herein are cell-based bioassays for measuring GLP-I receptor agonist activity of test compounds, such as GLP-I receptor agonist compounds. Exemplary GLP-I receptor agonist compounds include exendins, exendin analogs, GLP-1(7-37), and GLP-1(7-37) analogs. The bioassays are useful for quantitatively determining cAMP generated in samples containing GLP-I receptor agonist compounds (e.g., exenatide) and 6-23 (clone 6) cells having GLP-I receptors, whereby the amount of cAMP generated can be correlated to the GLP-I receptor agonist activity of the GLP-I receptor agonist compounds (e.g., exenatide). Suitable cell-based bioassays include enzyme-linked immunosorbent assays and homogeneous time-resolved fluorescence assays.
    Type: Grant
    Filed: May 15, 2009
    Date of Patent: December 11, 2012
    Assignees: Amylin Pharmaceuticals, LLC, Astrazeneca Pharmaceuticals LP
    Inventors: Michalis Nicolaou, Frederick Charles Bancroft, John Patrick Herich, Swati Gupta, Aung Naing Lwin
  • Quinuclidine derivatives as muscarinic M3 receptor antagonists
    Patent number: 8329729
    Abstract: The invention provides named compounds of formula (I), wherein R4 is a N-substituted quinuclidine (I) pharmaceutical compositions containing them and a process for preparing the pharmaceutical compositions. Their use in therapy for the treatment of conditions mediated by M3 muscarinic receptors, such as chronic obstructive pulmonary disease is also disclosed.
    Type: Grant
    Filed: May 13, 2008
    Date of Patent: December 11, 2012
    Assignees: Astrazeneca AB, Pulmagen Therapeutics Synergy Ltd.
    Inventors: Richard James Bull, Rhonan Lee Ford, Antonio Mete
  • Pyrazolylaminopyridine derivatives useful as kinase inhibitors
    Patent number: 8324252
    Abstract: This invention relates to novel compounds having the Formula (I) to their pharmaceutical compositions and to their methods of use. These novel compounds provide a treatment for cancer.
    Type: Grant
    Filed: February 1, 2006
    Date of Patent: December 4, 2012
    Assignee: Astrazeneca AB
    Inventors: Audrey Davies, Michelle Lamb, Paul Lyne, Tao Wang, Dingwei Yu, Peter Mohr, Bin Wang
  • 4-(3-chloro-2-fluoroanilino)-7-methoxy-6-{[1-(N-methylcarbamoyl-methyl)piperidin-4-yl]oxy}quinazoline, its pharmaceutically acceptable salts, and pharmaceutical compositions comprising the same
    Patent number: 8318752
    Abstract: The invention concerns quinazoline derivatives of Formula (I): wherein each of R1, X1, R2, R3, R5, n and m have any of the meanings defined in the description; processes for their preparation, pharmaceutical compositions containing them and their use in the manufacture of a medicament for use as an antiproliferative agent in the prevention or treatment of tumors which are sensitive to inhibition of EGF and erbB receptor tyrosine kinases.
    Type: Grant
    Filed: September 15, 2004
    Date of Patent: November 27, 2012
    Assignee: Astrazeneca AB
    Inventor: Bernard Barlaam
  • REDUCED MASS METFORMIN FORMULATIONS
    Publication number: 20120294936
    Abstract: The present invention relates to metformin extended release (XR) formulations with improved compactability to provide reduced mass tablets, granulations, and capsules.
    Type: Application
    Filed: November 12, 2010
    Publication date: November 22, 2012
    Applicants: ASTRAZENECA UK LIMITED, BRISTOL-MYERS SQUIBB COMPANY
    Inventors: Admassu Abebe, Kyle Martin, Jatin M. Patel, Peter Timmins
  • Piperidine derivatives
    Patent number: 8314127
    Abstract: The present invention provides a compound of a formula (I): wherein the variables are defined herein; to a process for preparing such a compound; and to the use of such a compound in the treatment of a chemokine (such as CCR3) mediated disease state.
    Type: Grant
    Filed: July 19, 2006
    Date of Patent: November 20, 2012
    Assignee: Astrazeneca AB
    Inventors: Talbir Austin, David O'Sullivan, Matthew Perry, Brian Springthorpe
  • Inhaler
    Patent number: D671207
    Type: Grant
    Filed: January 11, 2011
    Date of Patent: November 20, 2012
    Assignee: AstraZeneca UK Limited
    Inventors: Kajsa Bobjer, Camilla Lundström, Mårten Rittfeldt, Jonas Svennberg